HU Liqin, LIU Ruifang, MA Wentong, WANG Guowei. Research Advances and Challenges of miR-223 in Cardiovascular DiseaseJ. Medical Journal of Peking Union Medical College Hospital, 2025, 16(5): 1260-1265. DOI: 10.12290/xhyxzz.2024-0711
Citation: HU Liqin, LIU Ruifang, MA Wentong, WANG Guowei. Research Advances and Challenges of miR-223 in Cardiovascular DiseaseJ. Medical Journal of Peking Union Medical College Hospital, 2025, 16(5): 1260-1265. DOI: 10.12290/xhyxzz.2024-0711

Research Advances and Challenges of miR-223 in Cardiovascular Disease

  • Cardiovascular disease (CVD) is currently one of the most severe diseases endangering human health, encompassing myocardial ischemia syndrome, myocardial fibrosis, atrial fibrillation, and other conditions. MicroRNAs (miRNAs/miR) are a class of small non-coding RNAs that can bind to specific sequences and subsequently regulate post-transcriptional processing, translation, or epigenetic modifications, thereby modulating gene expression. Studies have found that miR-223 is associated with the occurrence and development of CVD and represents a potential specific therapeutic target. This article summarizes the relevant research on miR-223 in CVD, focusing on myocardial ischemia syndrome, myocardial fibrosis, and atrial fibrillation, and discusses its application prospects and challenges as a specific therapeutic target, providing new ideas for the diagnosis and treatment of CVD.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return